CNX Therapeutics is delighted to welcome Lee Debenham as our new Director of Scientific Affairs.
Lee has worked in the pharmaceutical industry for 24 years and joins CNX from Bristol-Myers Squibb where he was Associate Director RCEE, and previously held roles at Celgene and Allergan.
Lee will be leading the Quality, Regulatory and Pharmacovigilance teams at CNX, to support and drive the ambitious growth plans of the business whilst also ensuring we continue to meet the high industry standards which we currently do. He will also be leading initiatives at CNX to embrace technology and identify new digital solutions for continuous business improvement. His global experience in blue-chip pharmaceutical organisations will be critical as CNX continues to expand its European footprint, focused on commercialising a range of CNS and other important speciality medicines.
Lee says “I am very excited to be joining the wonderful team here at CNX Therapeutics. The opportunity to join the company at a time of growth and to help steer us in a compliant manner to achieve our goal of becoming a leading European speciality pharma provider is an opportunity that I wholeheartedly welcome”.